Lundbeck lifts full-year guidance after strong Q1 revenue and earnings growth

Investing.com -- Lundbeck (CSE:HLUNb) on Wednesday raised its full-year revenue and earnings guidance after reporting a 16% increase in first-quarter revenue at constant exchange rates to DKK 6.24 billion and a 24% rise in adjusted EBITDA to DKK 2.17 billion, supported by double-digit growth across its brands and strong sales in all regions.

Revenue grew 18% in reported Danish kroner. The company said all markets contributed to the increase, led by the United States, where revenue rose 25% at constant exchange rates to DKK 3.28 billion. 

Sales in Europe were up 16% at DKK 1.44 billion, while International Operations posted DKK 1.53 billion in revenue, a 4% increase at constant exchange rates.

Strategic brands accounted for DKK 4.80 billion in revenue, representing 77% of the company’s total. That marks a 24% year-over-year increase at constant exchange rates and 28% in Danish kroner. 

Among those products, Rexulti posted DKK 1.49 billion in sales, up 28% at constant exchange rates. 

Brintellix, marketed as Trintellix in some regions, generated DKK 1.25 billion, a 7% increase. Vyepti rose 62% to DKK 1.04 billion, while the Abilify long-acting injectable (LAI) franchise brought in DKK 1.01 billion, up 16%.

Adjusted EBITDA rose to DKK 2.17 billion, with an adjusted EBITDA margin of 34.9%, up 1.9 percentage points from the same period last year. 

The company said margin growth was driven by revenue gains, partially offset by higher research and development spending. 

EBITDA totaled DKK 2.14 billion, a 22% increase at constant exchange rates and 23% in reported currency.

Lundbeck has raised its revenue growth forecast for the full year from 7% to 10% to 8% to 11% based on its first-quarter results. 

In addition, the company revised its adjusted EBITDA growth guidance to 8% to 14%, from 5% to 11% previously. Trade policy or healthcare regulations are not included in the updated outlook because they assume a stable trade environment.

“Lundbeck has had a strong start to 2025 providing the opportunity to raise guidance,” President and CEO Charl van Zyl said in a company statement. “The growth is driven by Rexulti and Vyepti as we continue to reach more patients with innovative therapies. The excellent performance is complemented by a maturing pipeline and underlying transformation, positioning the company for long-term growth.”